JAB-8263
Phase 2Small molecule
JAB-8263 is one of 2 small molecule programs targeting Rheumatoid Arthritis (RA). It is currently in Phase 2.
1
Indications
3
Total Trials
2
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Rheumatoid Arthritis (RA)
#DrugCompanyPhaseTrials
1JAB-8263
JJacobio Pharmaceuticals Co., Ltd.
Phase 2
LY4213663
Eli LillyPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Patients With Advanced Solid Tumors1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JAB-8263. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details